en زیست شناسی ملکولی Molecular Biology مقالات اصلی Original Article <span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Background:</span></span></span></span></i></b><b><i> </i></b><span lang="EN-ID" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Systemic inflammation is one of hallmarks in chronic obstructive pulmonary disease (COPD), contributing to high morbidity and mortality due to elevated levels of interleukin-6 (IL-6) and reduced level of interleukin-10 (IL-10). Probiotics have the potential to reduce systemic inflammation through the gut-lung axis. This study aims to assess the effect of probiotics compared with an inhaled bronchodilator on serum IL-6 and IL-10 levels in mice model of COPD. </span></span></span></span></span></span></span></span></span><br> <span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-ID" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Methods:</span></span></span></span></i></b><span lang="EN-ID" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt"> This was an in vivo experimental study with a post-test only control group design. Thirty C57BL/6 mice were randomized into five groups; NC (healthy mice), PC (COPD induced mice); T1 (COPD mice treated with a bronchodilator), T2 (COPD mice treated with probiotics) and T3 (COPD mice treated with both a bronchodilator and probiotics). COPD was induced for 12 weeks, followed by a 6-week treatment period. After completing the treatment, serum IL-6 and IL-10 levels were measured using the enzyme-linked immunosorbent assay (ELISA). </span></span></span></span></span></span></span></span></span><br> <span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-ID" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Results:</span></span></span></span></i></b><span lang="EN-ID" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt"> The IL-6 levels in T2 group were reduced to levels comparable to the negative control group (13.5 vs 12.0 pg/ml respectively, p=0.84). The IL-10 levels were higher in T2 group compared to T1 group, however; this difference was not statistically significant (181.4 vs 155.0 respectively, p>0.05). </span></span></span></span></span></span></span></span></span><br> <span style="font-size:10pt"><span style="text-justify:inter-ideograph"><span style="line-height:normal"><span style="tab-stops:396.55pt"><span style="font-family:Calibri,sans-serif"><b><i><span lang="EN-ID" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt">Conclusion:</span></span></span></span></i></b><span lang="EN-ID" style="font-size:12.0pt"><span new="" roman="" style="font-family:" times=""><span style="color:black"><span style="letter-spacing:-.1pt"> In mice model of COPD, probiotics have been shown to lower IL-6 levels and, to a lesser extent, increased IL-10. As a result, probiotics may have a protective effect against systemic inflammation.</span></span></span></span></span></span></span></span></span> COPD, Inflammation, Interleukin-6, Interleukin-10, Probiotics. ​​​ 322 328 http://rbmb.net/browse.php?a_code=A-10-1553-1&slc_lang=en&sid=1 Andika Pradana andikapradana@usu.ac. 100319475328460020748 100319475328460020748 Yes Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia & Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Dina Keumala Sari 100319475328460020749 100319475328460020749 No Department of Nutrition, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia Muhammad Rusda 100319475328460020750 100319475328460020750 No Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia & Department of Obstetrics & Gynaecology, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Amira Permatasari Tarigan 100319475328460020751 100319475328460020751 No Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Wiwien Heru Wiyono whwiyono211258@gmail.com 100319475328460020752 100319475328460020752 No Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, University of Indonesia, Persahabatan Hospital, Jakarta, Indonesia. Noni Novisari Soeroso 100319475328460020753 100319475328460020753 No Department of Pulmonology and Respiratory Medicine, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia. Putri Chairani Eyanoer putrieyanoer@usu.ac.id 100319475328460020754 100319475328460020754 No Department of Preventive and Community Medicine, Universitas Sumatera Utara, Medan, Indonesia. Mustafa Mahmud Amin mustafa.mahmud@usu.ac.id 100319475328460020755 100319475328460020755 No Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia & Department of Psychiatry, Faculty of Medicine, Universitas Sumatera Utara, Medan, Indonesia.